<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02129608</url>
  </required_header>
  <id_info>
    <org_study_id>14-002370</org_study_id>
    <nct_id>NCT02129608</nct_id>
  </id_info>
  <brief_title>Low Level Laser Treatment (LLLT) and Lorcaserin for Weight Management</brief_title>
  <official_title>A Feasibility Pilot Comparing a Non-invasive Low Level Laser Therapy (LLLT) With Lorcaserin to Reduce Central Adiposity in Overweight Individuals.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Currently in the United States about 97 million adults are considered obese, accounting for
      about 33% of the American adult population (compared to 22.9% in 1988). Obesity, defined as a
      body mass index of 30.0 or higher, is accountable for 44% of the diabetes, 23% of the
      ischemic heart disease and between 7% and 41% of certain cancers. The Erchonia® Zerona™ 2.0
      Laser (which will be used in this study) has been approved by the FDA (K123237) as a
      non-invasive dermatological aesthetic treatment which can be used by individuals intending to
      reduce circumference of hips, waist, and thighs. Lorcaserin is a selective serotonin 2C
      (5-HT(2C)) receptor agonist. The exact mechanism of action is not known, but lorcaserin is
      believed to promote satiety and decrease food intake by activating 5-HT(2C) receptors on
      anorexigenic pro-opiomelanocortin neurons in the hypothalamus. Lorcaserin was approved by the
      FDA on June 2012 for weight management in people with a BMI of &gt; 27 kg/m2 (overweight) when
      accompanied by a weigh-related condition such as type 2 diabetes or high blood pressure or in
      people with a BMI &gt; 30 kg/m2 (obese). The purpose of this pilot study is to obtain
      preliminary data on: 1) effectiveness of the combination of LLLT and lorcaserin for reducing
      abdominal subcutaneous fat in overweight/obese individuals; 2) impact of LLLT on inflammatory
      biomarkers, blood sugar, and cholesterol.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is being done to find out how effective Low Level Laser Therapy (LLLT - Erchonia®
      Zerona™ 2.0 Laser) is compared to Lorcaserin (Belviq®) in helping overweight people reduce
      their weight gain - especially in the central body region. Subjects will undergo 2 screening
      visits in which the investigators will take their medical and weight concern histories; and
      if found eligible, they will be randomized to one of three groups: 1) 12 weeks of LLLT, 2) 12
      weeks of Lorcaserin, and 3) 12 weeks of a combination of both Lorcaserin and LLLT. Full study
      participation will last approximately 6 months and consists of 10 visits- 9 clinical and 1
      phone call. During this study subjects will be provided with weight prevention counseling and
      be asked to complete 3 additional fasting blood draws. There will be one urine pregnancy test
      (for females only) at the beginning of the study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Waist Circumference</measure>
    <time_frame>3 months</time_frame>
    <description>The change in waist circumference from baseline to 3 months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Weight</measure>
    <time_frame>3 months</time_frame>
    <description>The change in weight from baseline to 3 months</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Overweight</condition>
  <condition>Obese</condition>
  <arm_group>
    <arm_group_label>LLLT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Low Level Laser Therapy (LLLT) once a week for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lorcaserin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>locarserin monotherapy - 10 mg, twice daily for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LLLT and Lorcaserin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>LLLT once a week for 12 weeks and 10 mg of Lorcaserin twice daily for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>LLLT</intervention_name>
    <description>The LLLT uses 6 diode laser heads - each emitting 17 mW output. Subject will receive 30 minutes of therapy in the frontal central area and 30 minutes of therapy in the back central area, once a week for 12 weeks.</description>
    <arm_group_label>LLLT</arm_group_label>
    <arm_group_label>LLLT and Lorcaserin</arm_group_label>
    <other_name>Low Level Laser</other_name>
    <other_name>Erchonia® Zerona™ 2.0 Laser</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lorcaserin</intervention_name>
    <description>10 mg pills twice daily for 12 weeks.</description>
    <arm_group_label>Lorcaserin</arm_group_label>
    <arm_group_label>LLLT and Lorcaserin</arm_group_label>
    <other_name>Belviq</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  be 18-70 years of age;

          -  have a body weight of greater than 50 kg (110 pounds);

          -  have a BMI 27-39.9 kg/m2;

          -  be weight concerned;

          -  be motivated to reduce their central adiposity;

          -  be able to participate fully in all aspects of the study;

          -  have understood and signed study informed consent.

        Exclusion Criteria:

          -  have used weight loss medications or participated in a weight loss program within the
             past 30 days;

          -  are currently taking supplements known to affect weight, such as garcinia cambrogia.

          -  have had weight fluctuations of 20 pounds or more in the past 6 months (self-report);

          -  have an implanted device (including pacemaker or lap band) in the targeted area of
             LLLT;

          -  have an active untreated clinically significant psychiatric condition (psychosis,
             bipolar disorder, or depression);

          -  have used an investigational drug within 30 days of study enrollment;

          -  have a recent history (past 30 days) of alcohol or drug abuse or dependence;

          -  are currently pregnant or lactating, or are of child-bearing potential or are likely
             to become pregnant during the medication phase and are unwilling to use a reliable
             form of contraception;

          -  have a history of any major cardiovascular events including heart valve disease,
             cardiac arrhythmias, congestive heart failure, acute coronary syndrome, stroke,
             transient ischemic attack, or peripheral vascular disease;

          -  have current uncontrolled hypertension (systolic &gt; 165 mm Hg or diastolic &gt; 95 mm Hg)
             documented on 2 separate occasions;

          -  have clinically significant acute or chronic progressive or unstable neurologic,
             hepatic, renal, cardiovascular, lymphatic, respiratory, or metabolic disease (such as
             diabetes) or active cancer or are within 1 year of cancer remission;

          -  Prior surgical intervention for body sculpting/weight loss, such as liposuction,
             abdominoplasty, stomach stapling, lap band surgery, etc.;

          -  medical, physical, or other contraindications for body sculpting/weight loss;

          -  current use of medication(s) known to affect weight levels/cause bloating or swelling
             and for which abstinence during the course of study participation is not safe or
             medically prudent;

          -  concurrently taking a serotonergic drug (selective serotonin reuptake inhibitors
             (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase
             inhibitors (MAOIs), triptans, bupropion, dextromethorphan, St. John's Wort). These
             drugs can be used to treat depression and/or migraines but are contraindicated with
             lorcaserin;

          -  any medical condition known to affect weight levels and/or to cause bloating or
             swelling;

          -  diagnosis of, and/or taking medication for, irritable bowel syndrome;

          -  active infection, wound or other external trauma to the areas to be treated with the
             laser;

          -  known photosensitivity disorder;

          -  are allergic to lorcaserin;

          -  current active cancer or currently receiving treatment for cancer; or

          -  have a known history of any condition or factor judged by the investigator to preclude
             participation in the study or which might hinder adherence;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ivana T. Croghan, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://bmcobes.biomedcentral.com/articles/10.1186/s40608-016-0122-4</url>
  </link>
  <results_reference>
    <citation>Croghan IT, Ebbert JO, Schroeder DR, Hurt RT, Hagstrom V, Clark MM. A randomized, open-label pilot of the combination of low-level laser therapy and lorcaserin for weight loss. BMC Obes. 2016 Sep 29;3:42. eCollection 2016.</citation>
    <PMID>27708788</PMID>
  </results_reference>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 25, 2014</study_first_submitted>
  <study_first_submitted_qc>May 1, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 2, 2014</study_first_posted>
  <results_first_submitted>September 30, 2016</results_first_submitted>
  <results_first_submitted_qc>September 30, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 22, 2016</results_first_posted>
  <last_update_submitted>September 30, 2016</last_update_submitted>
  <last_update_submitted_qc>September 30, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Ivana Croghan</investigator_full_name>
    <investigator_title>PhD</investigator_title>
  </responsible_party>
  <keyword>overweight</keyword>
  <keyword>obese</keyword>
  <keyword>central adiposity</keyword>
  <keyword>Laser</keyword>
  <keyword>lorcaserin</keyword>
  <keyword>low level laser therapy</keyword>
  <keyword>belviq</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Overweight</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>LLLT</title>
          <description>Low Level Laser Therapy (LLLT) once a week for 12 weeks
LLLT: The LLLT uses 6 diode laser heads - each emitting 17 mW output. Subject will receive 30 minutes of therapy in the frontal central area and 30 minutes of therapy in the back central area, once a week for 12 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Lorcaserin</title>
          <description>locarserin monotherapy - 10 mg, twice daily for 12 weeks
Lorcaserin: 10 mg pills twice daily for 12 weeks.</description>
        </group>
        <group group_id="P3">
          <title>LLLT and Lorcaserin</title>
          <description>LLLT once a week for 12 weeks and 10 mg of Lorcaserin twice daily for 12 weeks
LLLT: The LLLT uses 6 diode laser heads - each emitting 17 mW output. Subject will receive 30 minutes of therapy in the frontal central area and 30 minutes of therapy in the back central area, once a week for 12 weeks.
Lorcaserin: 10 mg pills twice daily for 12 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>End of Treatment</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>LLLT</title>
          <description>Low Level Laser Therapy (LLLT) once a week for 12 weeks
LLLT: The LLLT uses 6 diode laser heads - each emitting 17 mW output. Subject will receive 30 minutes of therapy in the frontal central area and 30 minutes of therapy in the back central area, once a week for 12 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Lorcaserin</title>
          <description>locarserin monotherapy - 10 mg, twice daily for 12 weeks
Lorcaserin: 10 mg pills twice daily for 12 weeks.</description>
        </group>
        <group group_id="B3">
          <title>LLLT and Lorcaserin</title>
          <description>LLLT once a week for 12 weeks and 10 mg of Lorcaserin twice daily for 12 weeks
LLLT: The LLLT uses 6 diode laser heads - each emitting 17 mW output. Subject will receive 30 minutes of therapy in the frontal central area and 30 minutes of therapy in the back central area, once a week for 12 weeks.
Lorcaserin: 10 mg pills twice daily for 12 weeks.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
            <count group_id="B2" value="14"/>
            <count group_id="B3" value="15"/>
            <count group_id="B4" value="44"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45.4" spread="9.9"/>
                    <measurement group_id="B2" value="40.6" spread="11.5"/>
                    <measurement group_id="B3" value="45.4" spread="13.3"/>
                    <measurement group_id="B4" value="43.9" spread="11.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight (in kgs)</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="96.0" spread="15.3"/>
                    <measurement group_id="B2" value="94.4" spread="16.2"/>
                    <measurement group_id="B3" value="90.3" spread="14.0"/>
                    <measurement group_id="B4" value="93.5" spread="15.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>waist circumference (in cm)</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="105.3" spread="11.6"/>
                    <measurement group_id="B2" value="108.0" spread="15.7"/>
                    <measurement group_id="B3" value="100.9" spread="10.0"/>
                    <measurement group_id="B4" value="104.7" spread="12.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Waist Circumference</title>
        <description>The change in waist circumference from baseline to 3 months</description>
        <time_frame>3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>LLLT</title>
            <description>Low Level Laser Therapy (LLLT) once a week for 12 weeks
LLLT: The LLLT uses 6 diode laser heads - each emitting 17 mW output. Subject will receive 30 minutes of therapy in the frontal central area and 30 minutes of therapy in the back central area, once a week for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Lorcaserin</title>
            <description>locarserin monotherapy - 10 mg, twice daily for 12 weeks
Lorcaserin: 10 mg pills twice daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>LLLT and Lorcaserin</title>
            <description>LLLT once a week for 12 weeks and 10 mg of Lorcaserin twice daily for 12 weeks
LLLT: The LLLT uses 6 diode laser heads - each emitting 17 mW output. Subject will receive 30 minutes of therapy in the frontal central area and 30 minutes of therapy in the back central area, once a week for 12 weeks.
Lorcaserin: 10 mg pills twice daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Waist Circumference</title>
          <description>The change in waist circumference from baseline to 3 months</description>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.3" spread="4.1"/>
                    <measurement group_id="O2" value="-6.0" spread="7.3"/>
                    <measurement group_id="O3" value="-4.0" spread="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.398</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.436</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Weight</title>
        <description>The change in weight from baseline to 3 months</description>
        <time_frame>3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>LLLT</title>
            <description>Low Level Laser Therapy (LLLT) once a week for 12 weeks
LLLT: The LLLT uses 6 diode laser heads - each emitting 17 mW output. Subject will receive 30 minutes of therapy in the frontal central area and 30 minutes of therapy in the back central area, once a week for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Lorcaserin</title>
            <description>locarserin monotherapy - 10 mg, twice daily for 12 weeks
Lorcaserin: 10 mg pills twice daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>LLLT and Lorcaserin</title>
            <description>LLLT once a week for 12 weeks and 10 mg of Lorcaserin twice daily for 12 weeks
LLLT: The LLLT uses 6 diode laser heads - each emitting 17 mW output. Subject will receive 30 minutes of therapy in the frontal central area and 30 minutes of therapy in the back central area, once a week for 12 weeks.
Lorcaserin: 10 mg pills twice daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Weight</title>
          <description>The change in weight from baseline to 3 months</description>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.0" spread="4.4"/>
                    <measurement group_id="O2" value="-3.7" spread="3.3"/>
                    <measurement group_id="O3" value="-3.5" spread="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.070</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.950</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>LLLT</title>
          <description>Low Level Laser Therapy (LLLT) once a week for 12 weeks
LLLT: The LLLT uses 6 diode laser heads - each emitting 17 mW output. Subject will receive 30 minutes of therapy in the frontal central area and 30 minutes of therapy in the back central area, once a week for 12 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Lorcaserin</title>
          <description>locarserin monotherapy - 10 mg, twice daily for 12 weeks
Lorcaserin: 10 mg pills twice daily for 12 weeks.</description>
        </group>
        <group group_id="E3">
          <title>LLLT and Lorcaserin</title>
          <description>LLLT once a week for 12 weeks and 10 mg of Lorcaserin twice daily for 12 weeks
LLLT: The LLLT uses 6 diode laser heads - each emitting 17 mW output. Subject will receive 30 minutes of therapy in the frontal central area and 30 minutes of therapy in the back central area, once a week for 12 weeks.
Lorcaserin: 10 mg pills twice daily for 12 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Low Blood Pressure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Tingling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Ivana Croghan</name_or_title>
      <organization>Mayo Clinic</organization>
      <phone>507-266-1944</phone>
      <email>domcro@mayo.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

